DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

GENetic Education Risk Assessment and TEsting Study

Not Applicable

Active, not recruiting

Conditions: Candidates for Hereditary Pancreatic Cancer Testing

Interventions: Other: Doxy.me genetic education +/- Color Genomics genetic education
Other: Color Genomics genetic education

First Posted Date: 2018-12-03

Last Posted Date: 2024-12-27

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 1000

Registration Number: NCT03762590

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Mobile Health App to Mitigate the Metabolic Effects of Androgen Deprivation Therapy

Not Applicable

Completed

Conditions: Prostate Cancer

Interventions: Other: Mobile Health App
Other: Usual care

First Posted Date: 2018-12-03

Last Posted Date: 2023-06-22

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 10

Registration Number: NCT03761160

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Prospective Study of the Prosigna Assay on Neoadjuvant Clinical Decision-making in Women with HR+/Her2- Breast Cancer

Active, not recruiting

Conditions: Breast Cancer

Interventions: Other: Prosigna PAM-50 assay

First Posted Date: 2018-11-21

Last Posted Date: 2025-02-13

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 60

Registration Number: NCT03749421

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Avelumab and Radiation in Muscle-Invasive Bladder Cancer

Phase 2

Terminated

Conditions: Muscle Invasive Bladder Cancer
Bladder Cancer

Interventions: Drug: Avelumab
Radiation: Radiation

First Posted Date: 2018-11-20

Last Posted Date: 2025-02-27

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 14

Registration Number: NCT03747419

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL

Phase 1

Active, not recruiting

Conditions: Acute Lymphoblastic Leukemia ALL

Interventions: Drug: Ribociclib
Drug: Dexamethasone
Drug: Everolimus

First Posted Date: 2018-11-14

Last Posted Date: 2025-05-07

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 45

Registration Number: NCT03740334

Locations: 🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸
Nemours/Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States

and more 9 locations

Testing Feasibility of Motivational Interviewing for Patient-Reported Cancer Pain Goals

Not Applicable

Completed

Conditions: Other Cancer

Interventions: Behavioral: Motivational Interviewing

First Posted Date: 2018-11-09

Last Posted Date: 2022-04-25

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 54

Registration Number: NCT03736746

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndromes

Interventions: Drug: Prexasertib
Drug: Mitoxantrone
Drug: Etoposide
Drug: Cytarabine

First Posted Date: 2018-11-08

Last Posted Date: 2019-06-12

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 2

Registration Number: NCT03735446

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies

Phase 2

Terminated

Conditions: Hematologic Malignancy

Interventions: Device: ClinicMACs

First Posted Date: 2018-10-24

Last Posted Date: 2022-05-10

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 2

Registration Number: NCT03717480

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Smartphone Technology to Alleviate Malignant Pain (STAMP)

Not Applicable

Completed

Conditions: Pain Management
Cancer
Opioid Use

Interventions: Behavioral: Intervention Participants

First Posted Date: 2018-10-24

Last Posted Date: 2023-06-05

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 20

Registration Number: NCT03717402

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency

Phase 2

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: Testosterone Cypionate 100 MG/ML
Drug: Placebo

First Posted Date: 2018-10-23

Last Posted Date: 2025-01-29

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 137

Registration Number: NCT03716739

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Home Terms & Conditions Privacy Policy